A multicenter phase I trial of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814 in patients with solid tumors.

被引：6
|
作者：
van Bussel, Mark
Mau-Soerensen, Morten
Damstrup, Lars
Nielsen, Dorte
Verheul, Henk M. W.
Aftimos, Philippe Georges
De Jonge, Maja J.
Berghoff, Karin
Schellens, Jan H. M.
机构：
[1] Netherlands Canc Inst NKI, Amsterdam, Netherlands
[2] Rigshosp, Dept Oncol, Copenhagen, Denmark
[3] Merck KGaA, Darmstadt, Germany
[4] Herlev Hosp, Dept Oncol, Herlev, Denmark
[5] Canc Ctr, Dept Med Oncol, Amsterdam, Netherlands
[6] Inst Jules Bordet, Brussels, Belgium
[7] Erasmus MC, Canc Inst, Rotterdam, Netherlands
[8] Netherlands Canc Inst, Amsterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.2556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2556
引用
收藏
页数：5
相关论文
共 50 条
  • [41] DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by Zebularine
    Meador, Jarah A.
    Su, Yanrong
    Ravanat, Jean-Luc
    Balajee, Adayabalam S.
    CARCINOGENESIS, 2010, 31 (02) : 184 - 191
  • [42] ACTIVITY OF THE DNA-DEPENDENT PROTEIN-KINASE (DNA-PK) MAY REQUIRE 2 DISTINCT PROTEINS
    SUN, SS
    MALIK, NP
    LUGOAYALA, E
    VANCUROVA, I
    CARTER, TH
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 304 - 304
  • [43] The DNA-dependent protein kinase (DNA-PK) More than just a case of making ends meet?
    Hill, Richard
    Lee, Patrick W. K.
    CELL CYCLE, 2010, 9 (17) : 3460 - 3469
  • [44] The activity of the DNA-dependent protein kinase (DNA-PK) complex is determinant in the cellular response to nitrogen mustards
    Muller, C
    Calsou, P
    Salles, B
    BIOCHIMIE, 2000, 82 (01) : 25 - 28
  • [45] Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer
    Gordhandas, Sushmita B.
    Manning-Geist, Beryl
    Henson, Christina
    Iyer, Gopa
    Gardner, Ginger J.
    Sonoda, Yukio
    Moore, Kathleen N.
    Aghajanian, Carol
    Chui, M. Herman
    Grisham, Rachel N.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [46] Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer
    Sushmita B. Gordhandas
    Beryl Manning-Geist
    Christina Henson
    Gopa Iyer
    Ginger J. Gardner
    Yukio Sonoda
    Kathleen N. Moore
    Carol Aghajanian
    M. Herman Chui
    Rachel N. Grisham
    Scientific Reports, 12
  • [47] Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries
    Leahy, JJJ
    Golding, BT
    Griffin, RJ
    Hardcastle, IR
    Richardson, C
    Rigoreau, L
    Smith, GCM
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (24) : 6083 - 6087
  • [48] Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814
    Sun, Qing
    Guo, Yige
    Liu, Xiaohong
    Czauderna, Frank
    Carr, Michael I.
    Zenke, Frank T.
    Blaukat, Andree
    Vassilev, Lyubomir T.
    MOLECULAR CANCER RESEARCH, 2019, 17 (12) : 2457 - 2468
  • [49] DNA-Dependent Protein Kinase (DNA-PK)-Dependent Cisplatin-Induced Loss of Nucleolar Facilitator of Chromatin Transcription (FACT) and Regulation of Cisplatin Sensitivity by DNA-PK and FACT
    Dejmek, Janna
    Iglehart, J. Dirk
    Lazaro, Jean-Bernard
    MOLECULAR CANCER RESEARCH, 2009, 7 (04) : 581 - 591
  • [50] Activation of DNA-dependent protein kinase (DNA-PK) may play a role in apoptosis of human neuroblastoma cells
    Chakravarthy, BR
    Walker, T
    Rasquinha, I
    Hill, IE
    MacManus, JP
    JOURNAL OF NEUROCHEMISTRY, 1999, 72 : S51 - S51
12345